Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial-Reference-Cited by-同舟云学术

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Published:2021-09 Issue: Volume:154 Page:138-146
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Smith Matthew R.,Shore Neal,Tammela Teuvo L.,Ulys Albertas,Vjaters Egils,Polyakov Sergey,Jievaltas Mindaugas,Luz Murilo,Alekseev Boris,Kuss Iris,Le Berre Marie-Aude,Mohamed Ateesha F.,Odom Dawn,Bartsch Jennifer,Snapir Amir,Sarapohja Toni,Fizazi Karim

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Canc,2019

2. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019;Gillessen;Eur Urol,2020

3. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial;Saad;Lancet Oncol,2018

4. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial;Tombal;Lancet Oncol,2019

5. Managing nonmetastatic castration-resistant prostate cancer;Mateo;Eur Urol,2019

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis;Prostate International;2024-08

2. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

3. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR);The Oncologist;2024-03-07

4. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-02

5. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS;The Oncologist;2024-02-23